Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Scheltema MJ"" wg kryterium: Autor


Tytuł :
Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50
Autorzy :
Gielchinsky I
Scheltema MJ
Cusick T
Chang J
Shnier R
Moses D
Delprado W
Nguyen Q
Yuen C
Haynes A
Stricker PD
Pokaż więcej
Temat :
mpMRI
prostate cancer
young
sensitivity
Diseases of the genitourinary system. Urology
RC870-923
Źródło :
Research and Reports in Urology, Vol Volume 10, Pp 145-150 (2018)
Opis pliku :
electronic resource
Relacje :
https://www.dovepress.com/reduced-sensitivity-of-multiparametric-mri-for-clinically-significant--peer-reviewed-article-RRU; https://doaj.org/toc/2253-2447
Dostęp URL :
https://doaj.org/article/b4ec74adc1404b349a97e434a01ce1bf
Czasopismo naukowe
Tytuł :
Reply by Authors.
Autorzy :
Amin A
Scheltema MJ
Shnier R
Blazevski A
Moses D
Cusick T
Siriwardena A
Yuen B
van Leeuwen PJ
Haynes AM
Matthews J
Brenner P
O'Neill G
Yuen C
Delprado W
Stricker P
Thompson J
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2020 Oct; Vol. 204 (4), pp. 843-844. Date of Electronic Publication: 2020 Jul 01.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Multiparametric Magnetic Resonance Imaging*
Prostate*
Biopsy ; Magnetic Resonance Imaging ; Male ; Watchful Waiting
Czasopismo naukowe
Tytuł :
Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
Autorzy :
Blazevski A; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia. .; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia. .; St. Vincent's Clinical School, University of New South Wales, Sydney, Australia. .
Amin A; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Scheltema MJ; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands.
Balakrishnan A; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Haynes AM; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Barreto D; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Cusick T; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Thompson J; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Stricker PD; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Pokaż więcej
Źródło :
World journal of urology [World J Urol] 2020 Jun 02. Date of Electronic Publication: 2020 Jun 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Autorzy :
Blazevski A; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia. Electronic address: .
Scheltema MJ; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; Amsterdam UMC, Amsterdam, The Netherlands.
Yuen B; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Masand N; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia.
Nguyen TV; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia; School of Biomedical Engineering, University of Technology, Sydney, NSW, Australia.
Delprado W; Douglas Hanly Moir Pathology, Macquarie Park, NSW, Australia.
Shnier R; I-MED Radiology, Sydney, NSW, Australia.
Haynes AM; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Cusick T; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Thompson J; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia.
Stricker P; St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia.
Pokaż więcej
Źródło :
European urology oncology [Eur Urol Oncol] 2020 Jun; Vol. 3 (3), pp. 283-290. Date of Electronic Publication: 2019 May 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
3-Year Freedom from Progression After Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial.
Autorzy :
Emmett L; Department of Nuclear Medicine and Theranostics, St. Vincent's Hospital, Sydney, Australia .; Faculty of Medicine, University of New South Wales, Sydney, Australia.
Tang R; Department of Nuclear Medicine and Theranostics, St. Vincent's Hospital, Sydney, Australia.; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Sydney, Australia.
Nandurkar R; Faculty of Medicine, University of New South Wales, Sydney, Australia.
Hruby G; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia.; Genesis Cancer Care, Sydney, Australia.
Roach P; Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia.; Faculty of Medicine, University of Sydney, Sydney, Australia.
Watts JA; Department of Nuclear Medicine/Washington PET Services, Sir Charles Gairdner Hospital, Perth, Australia.; Faculty of Health and Medical Science, University of Western Australia, Perth, Australia.
Cusick T; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Sydney, Australia.
Kneebone A; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia.; Faculty of Medicine, University of Sydney, Sydney, Australia.
Ho B; Department of Nuclear Medicine and Theranostics, St. Vincent's Hospital, Sydney, Australia .
Chan L; Department of Nuclear Medicine and Theranostics, St. Vincent's Hospital, Sydney, Australia.
van Leeuwen PJ; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Scheltema MJ; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Sydney, Australia.; Department of Urology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Nguyen A; Department of Nuclear Medicine and Theranostics, St. Vincent's Hospital, Sydney, Australia.
Yin C; Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia.
Scott A; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia.
Tang C; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, Australia.
McCarthy M; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, Australia.
Fullard K; Department of Nuclear Medicine and Theranostics, St. Vincent's Hospital, Sydney, Australia.
Roberts M; Faculty of Medicine, University of Queensland, Brisbane, Australia.; Nepean Urology Research Group, Kingswood, New South Wales, Australia; and.
Francis R; Faculty of Health and Medical Science, University of Western Australia, Perth, Australia.; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, Australia.
Stricker P; Faculty of Medicine, University of New South Wales, Sydney, Australia.; Faculty of Medicine, University of Sydney, Sydney, Australia.; Department of Urology, St. Vincent's Hospital, Sydney Australia.
Pokaż więcej
Źródło :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2020 Jun; Vol. 61 (6), pp. 866-872. Date of Electronic Publication: 2019 Nov 01.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Membrane Glycoproteins*
Organometallic Compounds*
Prostatectomy*
Radiopharmaceuticals*
Neoplasm Recurrence, Local/*diagnostic imaging
Positron Emission Tomography Computed Tomography/*methods
Prostatic Neoplasms/*diagnostic imaging
Aged ; Disease Progression ; Gallium Radioisotopes ; Humans ; Male ; Middle Aged ; Prospective Studies ; Prostatic Neoplasms/surgery
Czasopismo naukowe
Tytuł :
The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
Autorzy :
Amin A; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.; School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
Scheltema MJ; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.; Department of Urology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Shnier R; I-MED Radiology, Sydney, New South Wales, Australia.
Blazevski A; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.; School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
Moses D; School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Cusick T; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
Siriwardena A; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
Yuen B; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
van Leeuwen PJ; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.
Haynes AM; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
Matthews J; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.
Brenner P; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.
O'Neill G; St Vincent's Clinic, Sydney, New South Wales, Australia.
Yuen C; School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.; St Vincent's Clinic, Sydney, New South Wales, Australia.
Delprado W; Douglas Hanly Moir Pathology, Macquarie Park, New South Wales, Australia.
Stricker P; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.; School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
Thompson J; St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.; School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Kinghorn Cancer Centre, Sydney, New South Wales, Australia.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2020 May; Vol. 203 (5), pp. 910-917. Date of Electronic Publication: 2019 Dec 11.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Biopsy/*statistics & numerical data
Early Detection of Cancer/*methods
Multiparametric Magnetic Resonance Imaging/*statistics & numerical data
Neoplasm Staging/*methods
Prostate/*pathology
Prostatic Neoplasms/*diagnosis
Aged ; Biopsy/methods ; Disease Progression ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiparametric Magnetic Resonance Imaging/methods ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Prostate-Specific Antigen/metabolism ; Prostatic Neoplasms/metabolism ; Time Factors
Czasopismo naukowe
Tytuł :
Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Autorzy :
Amin A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Blazevski A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Thompson J; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St George Clinical School, University of New South Wales, Sydney, NSW, Australia.
Scheltema MJ; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Department of Urology, UMC, Amsterdam, The Netherlands.
Hofman MS; Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia.
Murphy D; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Lawrentschuk N; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.; Department of Surgery, Austin Health, The University of Melbourne, Parkville, Vic., Australia.; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Vic., Australia.
Sathianathen N; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Kapoor J; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Woo HH; Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, NSW, Australia.; Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Chalasani V; University of Sydney, Sydney, NSW, Australia.
Rasiah K; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Department of Urology, Royal North Shore Private Hospital, St Leonards, NSW, Australia.
van Leeuwen PJ; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Tang R; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
Cusick T; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Stricker P; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2020 Apr; Vol. 125 (4), pp. 515-524. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji :
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, Surface*
Gallium Radioisotopes*
Glutamate Carboxypeptidase II*
Multiparametric Magnetic Resonance Imaging*
Positron Emission Tomography Computed Tomography*
Prostatic Neoplasms/*diagnostic imaging
Cross-Sectional Studies/methods ; Humans ; Male ; Multicenter Studies as Topic/methods ; Prospective Studies
Czasopismo naukowe
Tytuł :
Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
Autorzy :
Blazevski A; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Scheltema MJ; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands.
Amin A; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.
Thompson JE; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Lawrentschuk N; EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare, Melbourne, Victoria, Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Department of Surgery, Olivia Newton-John Cancer Centre, Austin Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Stricker PD; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2020 Mar; Vol. 125 (3), pp. 369-378. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Electroporation*
Ablation Techniques/*methods
Prostatic Neoplasms/*surgery
Biomedical Research ; Forecasting ; Humans ; Male
Czasopismo naukowe
Tytuł :
Diagnostic accuracy of Ga-PSMA PET to mpMRI.
Autorzy :
Scheltema MJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Amsterdam UMC, Department of Urology, Amsterdam, The Netherlands.
Chang JI; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Stricker PD; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
van Leeuwen PJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.
Nguyen QA; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Ho B; St Vincent's Hospital Nuclear Medicine and PET Department, Darlinghurst, NSW, Australia.
Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
Lee J; St Vincent's Hospital Nuclear Medicine and PET Department, Darlinghurst, NSW, Australia.
Thompson JE; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Cusick T; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Spriensma AS; Amsterdam UMC, Department of Urology, Amsterdam, The Netherlands.
Siriwardana AR; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Yuen C; St Vincent's Clinic, Darlinghurst, NSW, Australia.
Kooner R; St Vincent's Clinic, Darlinghurst, NSW, Australia.
Hruby G; Genesis Cancer Care, St Vincent's Hospital, Darlinghurst, NSW, Australia.
O'Neill G; St Vincent's Clinic, Darlinghurst, NSW, Australia.
Emmett L; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Hospital Nuclear Medicine and PET Department, Darlinghurst, NSW, Australia.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2019 Nov; Vol. 124 Suppl 1, pp. 42-49. Date of Electronic Publication: 2019 Jul 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Multiparametric Magnetic Resonance Imaging*
Positron Emission Tomography Computed Tomography*
Prostatectomy*
Gallium Radioisotopes/*pharmacology
Prostate/*pathology
Prostatic Neoplasms/*pathology
Radiopharmaceuticals/*pharmacology
Aged ; Dimensional Measurement Accuracy ; Health Care Surveys ; Humans ; Male ; Middle Aged ; Prostate/diagnostic imaging ; Prostate-Specific Antigen/analysis ; Prostatic Neoplasms/diagnostic imaging ; ROC Curve ; Reproducibility of Results ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
Autorzy :
Scheltema MJ; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, Sydney, NSW, Australia; St. Vincent's Prostate Cancer Centre, Department of Urology, Darlinghurst, Sydney, NSW, Australia; Academic Medical Center, Department of Urology, University of Amsterdam, The Netherlands. Electronic address: m.scheltema@garvan.org.au.
Chang JI; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, Sydney, NSW, Australia; St. Vincent's Prostate Cancer Centre, Department of Urology, Darlinghurst, Sydney, NSW, Australia.
van den Bos W; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, Sydney, NSW, Australia; St. Vincent's Prostate Cancer Centre, Department of Urology, Darlinghurst, Sydney, NSW, Australia.
Böhm M; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, Sydney, NSW, Australia.
Delprado W; University of Notre Dame, Sydney, NSW, Australia.
Gielchinsky I; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, Sydney, NSW, Australia; St. Vincent's Prostate Cancer Centre, Department of Urology, Darlinghurst, Sydney, NSW, Australia.
de Reijke TM; Academic Medical Center, Department of Urology, University of Amsterdam, The Netherlands.
de la Rosette JJ; Academic Medical Center, Department of Urology, University of Amsterdam, The Netherlands.
Siriwardana AR; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, Sydney, NSW, Australia; St. Vincent's Prostate Cancer Centre, Department of Urology, Darlinghurst, Sydney, NSW, Australia.
Shnier R; Southern Radiology, Randwick, Sydney, NSW, Australia.
Stricker PD; St. Vincent's Prostate Cancer Centre, Department of Urology, Darlinghurst, Sydney, NSW, Australia.
Pokaż więcej
Źródło :
European urology focus [Eur Urol Focus] 2019 Jul; Vol. 5 (4), pp. 585-591.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Electrochemotherapy*/methods
Multiparametric Magnetic Resonance Imaging*
Prostatic Neoplasms/*diagnostic imaging
Prostatic Neoplasms/*drug therapy
Aged ; Humans ; Male ; Middle Aged ; Neoplasm, Residual ; Prostatic Neoplasms/pathology ; Reproducibility of Results ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences.
Autorzy :
Scheltema MJ; Department of Urology, Amsterdam UMC, Meibergdreef 9, Room G4-249, Amsterdam, 1105 AZ, The Netherlands.
O'Brien TJ; Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA, USA.
van den Bos W; Department of Radiology, Amsterdam UMC, Amsterdam, the Netherlands.
de Bruin DM; Department of Urology, Amsterdam UMC, Amsterdam, the Netherlands.
Davalos RV; Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA, USA.
van den Geld CWM; Department of Chemical Engineering and Chemistry, Eindhoven University of Technology, Eindhoven, the Netherlands.
Laguna MP; Department of Urology, Istanbul Medipol University, Istanbul, Turkey Amsterdam UMC, Amsterdam, the Netherlands.
Neal RE 2nd; Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA, USA.
Varkarakis IM; Second Urology Department, National and Kapodistrian University of Athens, Sismanoglio Hospital, Athens, Greece.
Skolarikos A; Second Urology Department, National and Kapodistrian University of Athens, Sismanoglio Hospital, Athens, Greece.
Stricker PD; Department of Urology, St. Vincent's Prostate Cancer Centre, Sydney, Australia.
de Reijke TM; Department of Urology, Amsterdam UMC, Amsterdam, the Netherlands.
Arena CB; Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA, USA.
de la Rosette J; Department of Urology, Istanbul Medipol University, Istanbul, Turkey Amsterdam UMC, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
Therapeutic advances in urology [Ther Adv Urol] 2019 Jun 07; Vol. 11, pp. 1756287219852305. Date of Electronic Publication: 2019 Jun 07 (Print Publication: 2019).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
Autorzy :
Gielchinsky I; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Chang J; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Cusick T; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.; School of Medicine, University of New South Wales, Kensington, NSW, Australia.
Nguyen Q; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Yuen C; School of Medicine, University of New South Wales, Kensington, NSW, Australia.; St Vincent's Clinic, Sydney, NSW, Australia.
Savdie R; School of Medicine, University of New South Wales, Kensington, NSW, Australia.; St Vincent's Clinic, Sydney, NSW, Australia.
Böhm M; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Haynes AM; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Scheltema MJ; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Stricker PD; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; School of Medicine, University of New South Wales, Kensington, NSW, Australia.; St Vincent's Clinic, Sydney, NSW, Australia.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2018 Nov; Vol. 122 Suppl 5, pp. 35-41. Date of Electronic Publication: 2018 Nov 08.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatectomy*
Watchful Waiting*
Prostatic Neoplasms/*pathology
Prostatic Neoplasms/*therapy
Disease-Free Survival ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Neoplasm, Residual ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Retrospective Studies ; Risk Assessment/methods ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.
Autorzy :
Scheltema MJ; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia. m.scheltema@garvan.org.au.; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia. m.scheltema@garvan.org.au.; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.scheltema@garvan.org.au.
Chang JI; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia.
Böhm M; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.
van den Bos W; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia.
Blazevski A; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia.
Gielchinsky I; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia.
Kalsbeek AMF; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.
van Leeuwen PJ; Erasmus Medical Center, University of Rotterdam, Rotterdam, The Netherlands.
Nguyen TV; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.; UNSW, Sydney, NSW, Australia.; School of Biomedical Engineering, University of Technology, Sydney, Australia.
de Reijke TM; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Siriwardana AR; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia.; UNSW, Sydney, NSW, Australia.
Thompson JE; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, 370 Victoria Street, Sydney, NSW, 2010, Australia.; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia.
de la Rosette JJ; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Stricker PD; St Vincent's Prostate Cancer Centre, Sydney, NSW, Australia.
Pokaż więcej
Źródło :
World journal of urology [World J Urol] 2018 Sep; Vol. 36 (9), pp. 1383-1389. Date of Electronic Publication: 2018 Mar 28.
Typ publikacji :
Journal Article
MeSH Terms :
Quality of Life*
Robotic Surgical Procedures*
Electroporation/*methods
Prostatectomy/*methods
Prostatic Neoplasms/*surgery
Aged ; Humans ; Male ; Matched-Pair Analysis ; Middle Aged ; Organ Sparing Treatments ; Patient Reported Outcome Measures ; Propensity Score ; Prospective Studies ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments.
Autorzy :
Scheltema MJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; Amsterdam UMC, University of Amsterdam, the Netherlands.
Chang JI; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
van den Bos W; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst., St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Gielchinsky I; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia, St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Nguyen TV; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia,. University of New South Wales, Sydney, NSW, Australia.
Reijke TM; Amsterdam UMC University of Amsterdam, the Netherlands.
Siriwardana AR; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; University of New South Wales, Sydney, NSW, Australia.
Böhm M; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; Amsterdam UMC, University of Amsterdam, the Netherlands.
de la Rosette JJ; Amsterdam UMC, University of Amsterdam, the Netherlands, Department of Urology, İstanbul Medipol University, İstanbul, Turkey.
Stricker PD; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; Amsterdam UMC, University of Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
Diagnostic and interventional radiology (Ankara, Turkey) [Diagn Interv Radiol] 2018 Sep; Vol. 24 (5), pp. 268-275.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Electrochemotherapy/*methods
Prostate/*pathology
Prostatic Neoplasms/*psychology
Urogenital System/*pathology
Aged ; Electrochemotherapy/adverse effects ; Erectile Dysfunction/complications ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Outcome Assessment, Health Care ; Prospective Studies ; Prostate/surgery ; Prostatic Neoplasms/surgery ; Quality of Life/psychology ; Urogenital System/physiopathology
Czasopismo naukowe
Tytuł :
Confocal Laser Endomicroscopy and Optical Coherence Tomography for the Diagnosis of Prostate Cancer: A Needle-Based, In Vivo Feasibility Study Protocol (IDEAL Phase 2A).
Autorzy :
Swaan A; Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.; Department of Biomedical Engineering and Physics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Mannaerts CK; Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Scheltema MJ; Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Nieuwenhuijzen JA; Department of Urology, VU University Medical Center, VU University, Amsterdam, Netherlands.
Savci-Heijink CD; Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
de la Rosette JJ; Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.; Department of Urology, Istanbul Medipol University, Istanbul, Turkey.
van Moorselaar RJA; Department of Urology, VU University Medical Center, VU University, Amsterdam, Netherlands.
van Leeuwen TG; Department of Biomedical Engineering and Physics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
de Reijke TM; Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
de Bruin DM; Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.; Department of Biomedical Engineering and Physics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Pokaż więcej
Źródło :
JMIR research protocols [JMIR Res Protoc] 2018 May 21; Vol. 7 (5), pp. e132. Date of Electronic Publication: 2018 May 21.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases.
Autorzy :
Thompson JE; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; The University of New South Wales, Kensington, NSW, Australia. Electronic address: .
Egger S; Cancer Council NSW, Woolloomooloo, NSW, Australia.
Böhm M; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Siriwardana AR; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Haynes AM; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Matthews J; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Scheltema MJ; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; Academic Medical Center, Amsterdam, The Netherlands.
Stricker PD; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; The University of New South Wales, Kensington, NSW, Australia.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2018 May; Vol. 73 (5), pp. 664-671. Date of Electronic Publication: 2017 Dec 19.
Typ publikacji :
Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Quality of Life*
Neoplasm Recurrence, Local/*pathology
Prostatectomy/*methods
Prostatic Neoplasms/*surgery
Robotic Surgical Procedures/*methods
Aged ; Cohort Studies ; Disease-Free Survival ; Humans ; Learning Curve ; Linear Models ; Logistic Models ; Male ; Margins of Excision ; Middle Aged ; Multivariate Analysis ; Neoplasm Invasiveness/pathology ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/surgery ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/psychology ; Risk Assessment ; Survival Analysis ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Focal irreversible electroporation as primary treatment for localized prostate cancer.
Autorzy :
van den Bos W; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Scheltema MJ; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Siriwardana AR; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Kalsbeek AMF; Garvan Institute of Medical Research and Kinghorn Cancer Centre.
Thompson JE; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Ting F; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Böhm M; Garvan Institute of Medical Research and Kinghorn Cancer Centre.
Haynes AM; Garvan Institute of Medical Research and Kinghorn Cancer Centre.
Shnier R; Southern Radiology, Randwick.
Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
Stricker PD; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2018 May; Vol. 121 (5), pp. 716-724. Date of Electronic Publication: 2017 Sep 04.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Electroporation*/methods
Ablation Techniques/*methods
Neoplasm Recurrence, Local/*therapy
Prostate/*pathology
Prostatic Neoplasms/*therapy
Aged ; Feasibility Studies ; Humans ; Male ; Middle Aged ; Patient Safety ; Prospective Studies ; Quality of Life ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Treatment Outcomes from Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.
Autorzy :
Emmett L; Department of Diagnostic Imaging, St. Vincent's Public Hospital, Sydney, Australia .; The Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Sydney, Australia.; University of New South Wales (UNSW), Sydney, New South Wales, Australia.
van Leeuwen PJ; The Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Sydney, Australia.
Nandurkar R; University of New South Wales (UNSW), Sydney, New South Wales, Australia.
Scheltema MJ; The Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Sydney, Australia.
Cusick T; The Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Sydney, Australia.; Australian Prostate Cancer Research Centre, New South Wales, Australia.
Hruby G; Australian Prostate Cancer Research Centre, New South Wales, Australia .; Genesis Cancer Care, Sydney, Australia.
Kneebone A; Australian Prostate Cancer Research Centre, New South Wales, Australia.; Genesis Cancer Care, Sydney, Australia.
Eade T; Australian Prostate Cancer Research Centre, New South Wales, Australia.; Genesis Cancer Care, Sydney, Australia.
Fogarty G; Genesis Cancer Care, Sydney, Australia.
Jagavkar R; Genesis Cancer Care, Sydney, Australia.
Nguyen Q; The Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Sydney, Australia.; Australian Prostate Cancer Research Centre, New South Wales, Australia.
Ho B; University of New South Wales (UNSW), Sydney, New South Wales, Australia.
Joshua AM; The Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Sydney, Australia.
Stricker P; Department of Diagnostic Imaging, St. Vincent's Public Hospital, Sydney, Australia.; The Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Sydney, Australia.
Pokaż więcej
Źródło :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 Dec; Vol. 58 (12), pp. 1972-1976. Date of Electronic Publication: 2017 Jul 26.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatectomy*
Neoplasm Recurrence, Local/*diagnostic imaging
Neoplasm Recurrence, Local/*radiotherapy
Positron Emission Tomography Computed Tomography/*methods
Prostatic Neoplasms/*diagnostic imaging
Prostatic Neoplasms/*radiotherapy
Aged ; Antigens, Surface ; Combined Modality Therapy ; Edetic Acid/analogs & derivatives ; Follow-Up Studies ; Glutamate Carboxypeptidase II ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Oligopeptides ; Organometallic Compounds ; Patient Care Management ; Prognosis ; Prostate-Specific Antigen/analysis ; Prostatic Neoplasms/pathology ; Radiopharmaceuticals ; Salvage Therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Autorzy :
Scheltema MJ; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
van den Bos W; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Siriwardana AR; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Kalsbeek AMF; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Thompson JE; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Ting F; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Böhm M; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Haynes AM; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
Shnier R; Southern Radiology, Randwick, NSW, Australia.
Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
Stricker PD; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2017 Nov; Vol. 120 Suppl 3, pp. 51-58. Date of Electronic Publication: 2017 Sep 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Ablation Techniques/*adverse effects
Ablation Techniques/*methods
Neoplasm Recurrence, Local/*therapy
Prostatic Neoplasms/*therapy
Salvage Therapy/*adverse effects
Salvage Therapy/*methods
Aged ; Feasibility Studies ; Humans ; Male ; Neoplasm Recurrence, Local/epidemiology ; Prostatic Neoplasms/epidemiology ; Quality of Life ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.
Autorzy :
Tay KJ; Duke Cancer Institute, Duke University, Durham, NC, USA.
Scheltema MJ; Department of Urology, Academic Medical Center, Amsterdam, The Netherlands.
Ahmed HU; Division of Surgery and Interventional Science, University College of London, London, UK.
Barret E; L'Institut Mutualiste Montsouris, Paris-Descartes University, Paris, France.
Coleman JA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dominguez-Escrig J; Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain.
Ghai S; University of Toronto, Toronto, ON, Canada.
Huang J; Department of Pathology, Duke University, Durham, NC, USA.
Jones JS; Cleveland Clinic, Cleveland, OH, USA.
Klotz LH; Sunnybrook Medical Center, Toronto, ON, Canada.
Robertson CN; Duke Cancer Institute, Duke University, Durham, NC, USA.
Sanchez-Salas R; L'Institut Mutualiste Montsouris, Paris-Descartes University, Paris, France.
Scionti S; Saratosa Prostate Cancer Center, Sarasota, FL, USA.
Sivaraman A; L'Institut Mutualiste Montsouris, Paris-Descartes University, Paris, France.
de la Rosette J; Department of Urology, Academic Medical Center, Amsterdam, The Netherlands.
Polascik TJ; Duke Cancer Institute, Duke University, Durham, NC, USA.
Pokaż więcej
Źródło :
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2017 Sep; Vol. 20 (3), pp. 294-299. Date of Electronic Publication: 2017 Mar 28.
Typ publikacji :
Consensus Development Conference; Journal Article
MeSH Terms :
Patient Selection*
Prostatic Neoplasms/*radiotherapy
Humans ; Male ; Prostatic Neoplasms/diagnostic imaging
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies